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Objectives
Previous studies reported inherited BRCA1/2 deficits appear to cause cancer by 
impairing normal protective responses to some carcinogens.   Opportunistic carcinogens can 
exploit these deficits by causing chronic inflammation, constant cell death and replacement in 
a mutagenic environment, DNA crosslinking or double strand breaks.  Some of the resulting 
cancers may be prevented if BRCA1/2 specific carcinogens are identified.
Methods
The literature was systematically searched for carcinogens capable of exploiting defi-
cits in BRCA1/2 pathways.   Search criteria were common exposure, available information, 
required BRCA1/2 pathway repairs, increased risks for any cancer, and effects on stem cells.
Results
Formaldehyde and acetaldehyde are closely related carcinogens and common pol-
lutants that are everywhere. Alcohol metabolism also produces acetaldehyde.  High levels of 
either carcinogen overwhelm normal detoxification systems, cause inflammation, inhibit DNA 
repair and produce DNA cross links as critical carcinogenic lesions.  Searching model system 
studies revealed both carcinogens activate stem cells, BRCA1/2 pathways and connected 
BRCA1/2 pathways to myeloid leukemia.  For example, the BRCA1-BARD1 complex is re-
quired for proper nucleophosmin functions.  Nucleophosmin prevents a major subset of acute 
myeloid leukemia (AML).  Next, these concepts were independently tested against risks for 
myeloid leukemia.  Epidemiologic results showed that BRCA2 gene defects inherited on both 
chromosomes increased risks so dramatically that AML occurs in most children.  Using data 
from 14 studies, known/potential heterozygous BRCA1/BRCA2 mutations increased risks for 
myeloid leukemias by at least 3 fold in 7 studies and by at least 50% in 12.  
Acetaldehyde occurs in breast milk.  In model studies, excessive acetaldehyde/alcohol 
exposure affects estrogen metabolism and stimulates alternate alcohol detoxification path-
ways.  These pathways can cause DNA cross linking by releasing oxygen species and activating 
procarcinogens.  Acetaldehyde in rats’ drinking water increased incidence of leukemias, lym-
phomas, pancreatic cancers and fibroadenomas.  Human epidemiologic studies showed in-
creased premenopausal breast cancer risks associated with persistent/high acetaldehyde levels 
related to alcohol metabolism genotype.  
Conclusions  
Although it is difficult to prove direct causation, BRCA1/2 mutation carriers may 
reduce cancer risks by avoiding excessive formaldehyde and acetaldehyde.  Broader genetic 
testing and pharmacologic/nutritional detoxification are possible.  
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Background
Previous explanations for the tis-
sue specificity of hereditary breast cancer.   
BRCA1 and BRCA2 mutations were thought to 
have an exquisite specificity in causing breast and 
ovarian cancer.  Published explanations either 
required some unique, tissue specific property 
of BRCA1/2 genes,  depended on the context 
of other expressed genes, or on the absence of 
backup systems specific for tissues where tumors 
develop,    
One idea is that cancer occurs in the 
breast because the breast does not have back 
up systems or redundancy to compensate for 
the absence of BrCA1/2 functions.  Back ups for 
some BRCA1/2 function are general methods 
of DNA repair such as non-homologous end 
joining, or translesion synthesis.  These systems 
have wide tissue distribution.  When forced into 
service inappropriately because of abnormal 
BRCA1/2 pathways, repairs become less accurate 
and risks for some cancers increase.  [e.g.  Ven-
kitaraman (2003), Lagerqvist (2007), Friedenson 
(2007)].  Cancers that depend on gene transloca-
tions may occur because double strand breaks 
are repaired by combining the wrong pieces of 
broken chromosomes.   One cancer strongly 
associated with a reciprocal translocation is 
mantle cell lymphoma.  The incidence of mantle 
cell lymphoma increased 70 fold when the path-
way molecule ATM was inactivated [Friedenson, 
2007].  At least in some cases, losses of whole 
chromosomes or fragments are so fundamental 
and essential that alternative mechanisms in dif-
ferent tissues are unable to compensate without 
increasing mutations.  Repair or bypass of lesions 
using alternative methods has been documented, 
but this is known to increase the rates of muta-
tion [Lagerqvist et al.  (2008)].
A related proposal is that cells that lose 
both copies of BRCA1 are only able to survive 
in breast and ovary but die everywhere else.  
However there are homozygous defects if not in 
BRCA1, then in BRCA2,  ATM and Fanconi pro-
teins.  In these conditions every organ survives.
Another proposal depends on the high 
proliferation rates in the breast and ovary.  Cell 
proliferation in the absence of BRCA1 or BRCA2 
may lead to a higher mutation rate.  However 
breast cancer and leukemias provided founda-
tions for the cancer stem cell hypotheses.  This 
hypothesis states that cancers originate from 
stem cells that give rise to cancer, are capable 
of self renewal, differentiate asymmetrically but 
ordinarily do not proliferate.  Past results show 
that continual proliferation in a mutagenic envi-
ronment undoubtedly contributes [Friedenson 
2010a,b]. 
Another possibility is that tissue specific 
cofactors, transcription factors, hormones and 
the context of different tissues determine the 
tissue specificity of hereditary cancers.  However 
there are increased relative risks for cancers in 
a wide variety of tissues and increased risks for 
cancers in general.  
Because of such problems with previous 
explanations for the tissue specificity of BRCA1/2 
associated cancers, an alternate explanation 
for the tissue specificities of hereditary cancer 
was developed.  Previous results suggested that 
hereditary cancers have defects in processing 
some carcinogens from the environment be-
cause hereditary defects aggravate the effects of 
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some carcinogens.  Thus there was an increased 
incidence of cancers caused by organ specific 
infections that cause DNA damage requiring 
BRCA1/2 repairs.   Other genes that encode for 
immune responses, for processing, detoxifying 
or metabolizing carcinogens are a first defense 
against these carcinogen induced cancers.  
The literature was systematically 
searched to identify opportunistic carcinogens 
that act by exploiting deficits in BRCA1/2 path-
ways.   Initial search criteria were common ex-
posure, available information, required BRCA1/2 
pathway repairs, increased risks for any cancer, 
and effects on stem cells. Conclusions were then 
tested against the ability of carcinogens to cause 
tissue specific cancers by exploiting known he-
reditary deficits along routes of exposure.
Methods
Links among mutations in BRCA1/2 
pathways and common carcinogens.  
Searches were conducted for common carcino-
gens that produce DNA cross links or DNA 
protein cross links.  Formaldehyde and acetal-
dehyde were identified as two common pollut-
ants that form DNA lesions requiring BRCA1/2 
pathway repairs.  Both chemicals are carcinogens 
with known or suspected links to myeloid leuke-
mia.  Literature describing myeloid leukemia was 
searched for relationships to pathways mediated 
by BRCA1/2 gene products.
Risks for cancers associated with 
common environmental carcinogens in 
carriers of mutations in BRCA1/2 path-
ways.  Cancer survivors are often followed pro-
spectively for treatment response and complica-
tions, as well as disease progression. Given the 
high risk of BRCA1/2 mutation carriers and their 
involvement with medical oncology personnel, 
cancer survivors among patients with BRCA1/2 
pathway mutations have often been monitored 
for the development of a second primary cancer.  
This is more often done than to observe geneti-
cally typed healthy individuals for the develop-
ment of a first cancer.   Thus studies of second 
primary cancers provided the most extensive and 
complete sources of data.  
As previously described [Friedenson 
(2005, 2007, 2010a,b)], the literature was system-
atically searched for relative risk data on second 
primary cancers in carriers or likely carriers of 
mutations in genes encoding pathways that de-
pend on BRCA1/2 genes.  Data found in appro-
priate studies was used directly without further 
statistical calculation or combination.  No exclu-
sions were made for percentages of mutation 
carriers in the population, for survival, or for loss 
of subjects to follow-up.  
Results
Formaldehyde and acetaldehyde were 
identified for this study because exposure is 
common; risks for several cancers increase;  
much information is available; there are connec-
tions with BRCA1/2 pathways, and both have 
effects on stem cells.  [Zhang et al. (2010), Agency 
for toxic substances and disease registry (2010), 
Baan et al. (2009), US Dept Health and Human 
Services (1999), National Toxicology program 
(2011)].   
Common and widespread exposure.  
Formaldehyde and acetaldehyde are chemically 
closely related.  Both are common pollutants.  
Widespread human exposures to formaldehyde 
and acetaldehyde occur during manufacture and 
use of many maufactured products.  Many mil-
lions of pounds of each chemical are produced 
each year [Agency for toxic substances and 
disease registry (2010), Baan et al. (2009), Haupt-
mann et al. (2009),  National Toxicology Program 
(2010), Andersen et al. (2010), Friedenson, 2011].   
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Figure 1  - Carcinogenesis at high levels of formaldehyde 
competes with formaldehyde detoxification mechanisms.  
Detoxification of low levels of formaldehyde occurs primarily 
by a pathway (thicker arrows) involving formaldehyde dehy-
drogenase (ADH1C*1 or ADH1C*2), an aldehyde dehydroge-
nase.  The pathway converts formaldehyde to formate which 
is then eliminated in the urine, broken down to CO2 and 
water or enters the single carbon pool.  Alternate, less used 
pathways are indicated by thinner arrows.  Detoxification 
does not involve BRCA1/2 but BRCA1/2 pathways inhibit 
carcinogenesis.  
These carcinogens are also present 
in some foods and acetaldehyde is a 
metabolite of alcohol metabolism.   
Formaldehyde and acetaldehyde 
are opportunistic carcinogens 
causing DNA damage that re-
quires repairs by BRCA1/2 path-
ways.  
Formaldehyde and acetalde-
hyde chemically cross-link strands of 
DNA to each other and to nearby 
proteins (Fig. 1).  These lesions are 
probably critical for formaldehyde car-
cinogenesis [Zhang et al (2010)] and 
have been demonstrated by a large 
number of studies in vitro, in exposed 
animals and in circulating lympho-
cytes of exposed people [Zhang et 
al. (2010)]  Acetaldehyde also causes 
DNA protein cross links (Figure 2).   
Carriers of mutations in 
BRCA1 or BRCA2 genes are deficient 
in the ability to repair cross-linked 
DNA.  Homologous recombination 
involving pathways containing BRCA1/2 
has been demonstrated as essential to 
correct DNA protein cross links [Yam-
azoe et al.  (2004), Nojima et al. (2005)].  
Many studies in model systems support 
roles for BRCA-Fanconi pathways in 
repairing DNA protein cross links.
Formaldehyde can exist as 
polymers of varying length which may 
form cross linkers with varying reach.  The 
reactions of formaldehyde in DNA-protein 
mixtures, have been studied using mixtures 
of deoxynucleosides and amino acids as 
model compounds Cross-linked products 
that were chemically irreversible, stable 
and readily isolated were formed with 
the amino acids cysteine, histidine and 
tryptophan.  These products would form protein 
DNA cross links requiring BRCA1/2 pathway 
mediated repairs [Nakano et al (2003, 2007)].  
Lysine cross-linked products were labile in solu-
tion, supporting widely reported reversibility of 
formaldehyde-induced cross-links between lysine 
rich histones and DNA [Lu et al. (2010)].
In mice,  the Brca pathway is among the 
top 10 most significantly enriched pathways after 
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Figure 2a. Normal detoxification of alcohol requires two 
enzymes, alcohol dehydrogenase (ADH) and then al-
dehyde dehydrogenase (ALDH).  Alcohol dehydrogease 
produces acetaldehyde, a mutagen and carcinogen.  Geno-
types for both enzymes influence the susceptibility to 
alcohol related carcinogenesis.  Fig 2b.   One mechanism 
or carcinogenesis.    Acetaldehyde that escapes detoxi-
fication pathways can form crotonaldehyde, a reaction 
catalyzed by amine groups from proteins or naturally oc-
curring amines.   Crotonaldehyde is genotoxic, mutagenic 
and carcinogenic and can be derived from beer, wine and 
liquor.  Reactions with deoxyguanosine in DNA produce 
DNA interstrand cross links and DNA protein cross links 
[Theravathu et al (2005)].  Some of these lesions require 
repairs by BRCA1/2 pathways.  Inherited mutations within 
these pathways disable cross link repairs and can lead to 
cancer in exposed organs.  Excessive alcohol/acetaldehyde 
can also affect estrogen adding to cancer risks.
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1 week of exposure to 6 ppm formal-
dehyde  [Andersen et al, 2010].  
DNA-protein cross-links ex-
hibit a dose-response relationship to 
formaldehyde exposure in the respi-
ratory tract of laboratory animals at 
exposure concentrations relevant to 
human exposures.  In peripheral white 
blood cells of occupationally exposed 
workers,  DNA-protein cross-links 
increased significantly vs. controls and 
had a linear relationship with years of 
exposure [Shaham et al. (1996)].
BRCA1/2 related pathways 
also participate in preventing form-
aldehyde related collateral DNA 
damage e.g. bone marrow toxicity 
and immunosuppression (which can 
reactivate latent viral infections), and 
inflammation (which can produce 
cross-links due to oxidative damage). 
This collateral damage generates a 
mutagenic environment and increases 
the probability that AML stem cells 
will arise.
Alcohol consumption is caus-
ally related to an increased risk of 
cancer of the upper aerodigestive 
tract, liver, colorectum, and female 
breast.  Several lines of evidence 
indicate that acetaldehyde, the first 
product of alcohol metabolism, plays a 
very important role in alcohol-related 
carcinogenesis.  Excess acetaldehyde 
generated from alcohol metabolism 
can also produce DNA lesions that 
form interstrand crosslinks (Fig 2)  
Acetaldehyde exposure results in a 
concentration-dependent increase in 
Fanconi D2 monoubiquitination, which 
is dependent upon the proper func-
tioning of the pathway.  Acetaldehyde 
also stimulates BRCA1 phosphory-
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Figure 3  - BRCA1 and BRCA2 in DNA damage repair pathways showing prob-
able links to myeloid leukemia, other leukemias and lymphomas.  BRCA1 and 
BRCA2 are shown in pathways to correct DNA cross links and double strand 
breaks caused by formaldehyde, acetaldehyde and other agents that cause bulky 
addition products or DNA cross-links.   DNA damage is more likely if the car-
cinogen escapes metabolic detoxification pathways (Fig. 1).  Hereditary inacti-
vation of a Fanconi gene causes Fanconi anemia,  inactivation of the ATM gene 
causes ataxia-telangiectasia (A-T), and inactivation of BRCA1 or BRCA2 associ-
ates with hereditary breast/ovarian cancers.  Proteins encoded by genes related 
to these well known hereditary cancer conditions are colored red.  The dark box-
es in the figure indicate proven links to myeloid leukemia.  The BRCA1-BARD1 
complex is required to activate the NPM gene which is lost in a subset of AML.   
In AML and CML, the BCR/ABL protein interferes with the formation of nuclear 
Fanconi protein D2 repair foci.  In CML, BRCA1 becomes almost undetectable.  
The PML protein is required for Rad51 repair focus formation providing another 
link to leukemia.  Family history of leukemia increases risk for breast cancer.   
Chromosome 13q is deleted in a subgroup of leukemias and lymphomas.  Multi-
ple other pathways also participate in repairing DNA damage but the pathway 
shown has been implcated in coordinating repairs..   
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lation in a dose-dependent manner.   Thus the 
pathways required to repair DNA damage from 
acetaldehye is qualitatively similar to pathways 
required to repair damage from mitomycin C.  
Mitomycin C is a known DNA crosslinking agent 
that has become a functional test for activity of 
pathways involving Fanconi proteins [Marietta et 
al (2009)].  
Detoxification by specialized meta-
bolic pathways.  Normal metabolism produces 
both aldehydes and they occur naturally in foods.  
These background sources are generally too low 
to cause permanent harm and are managed by 
reactions and metabolism within the digestive 
tract.   Formaldehyde is primarily metabolized by 
glutathione-dependent formaldehyde dehydro-
genase (ADH3, existing in two forms renamed 
as ADH1C*1 or ADH1C*2) and aldehyde de-
hydrogenases (ALDHs) enzymes in alternative 
pathways (Fig. 1).  Formaldehyde is converted to 
formate, which is then eliminated in the urine as 
a sodium salt, broken down to CO2 and water, 
or entered into the single-carbon pool [Teng et 
al. (2001, Andersen et al, (2010)].    Other alcohol 
and aldehyde dehydrogenases can also contribute. 
Alcohol metabolism generates acetaldehyde and 
utilizes ADH and ALDH enzymes (Fig 2).   
DNA cross-links, chromosome breaks 
and chromosome abnormalities are favored if 
environmental formaldehyde or acetaldehyde 
exceeds the capacity of metabolizing detoxifica-
tion pathways (Figs 1 and 2).   For formaldehyde, 
exogenous addition products form with DNA in 
a highly nonlinear fashion; a 21.7-fold increase in 
exposure of rats to labeled formaldehyde caused 
a 286-fold increase in DNA-formaldehyde addi-
tion products [Lu et al. (2011)].   For both alde-
hydes different variants of the genes encoding 
detoxification enzymes can contribute to differ-
ences in cancer sensitivities (Fig 2a)  
A model for pathways contain-
ing BRCA1/2 has several strong links to 
leukemias - cancers that can be induced 
by formaldehyde or acetaldehyde (Fig. 
3).  Table 1 summarizes relationships between 
BRCA1/2 pathways in Fig 3  and myeloid leu-
kemias.  Children born with defects on both 
chromosomes that affect the BRCA1/2 / Fanconi 
pathway are at high risk for AML.   These defects 
include those in BRCA2 (Fanconi protein D1 and 
in PALB2(Fanconi protein N).  
A characteristic fusion protein (BCR/
ABL) is found in AML (and in CML) that inter-
feres with the formation of nuclear FANCD2 
foci (Fig. 3), but this interference can be reversed 
by the ectopic expression of BRCA1.  In CML, 
BRCA1 becomes virtually undetectable [Valeri et 
al (2010)].  
Mutations in nucleolar phosphoprotein 
nucleophosmin/B23 (NPM) are associated with a 
major subset of AML.   BRCA1-BARD1 catalyzes 
the polyubiquitination of NPM and this may be 
essential for several NPM functions. The NPM 
gene encodes a phosphoprotein that moves 
between the nucleus and the cytoplasm.   NPM 
colocalizes with BRCA1 and BARD1 in mitotic 
cells.  The heterodimer BRCA1-BARD1 catalyzes 
the ubiquitination of NPM in vitro and in vivo, 
and BRCA1-BARD1 co-expression in cells causes 
NPM stabilization rather than degradation [Sato 
et al (2004)] Familial AML is linked to the loss of 
the long arm of chromosome 5 which includes 
the NPM gene on chromosome 5q33–34.  5q33-
34 contains one or more genes that modify 
breast cancer risk in BRCA1 mutation carriers 
[Nathanson and Weber (2002)].  
Biallelic Fanconi N (PALB2) mutations are 
associated with AML and other pediatric malig-
nancies [Tischkowitz and Xia (2010)].  Fanconi 
protein A is lost in a subset of sporadic AML 
[Tischkowitz et al (2004)]  Casorelli et al (2006) 
found that impaired recombination repair stimu-
lated aPL.   Quantitative real time PCR and mi-
croarray data, showed reductions ranging from 3 
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Table 1  Connections between BRCA1/2 containing pathways and leukemias
Leukemia Evidence for connections to BRCA1/2 pathway Reference
AML
Childen born with defects on both chromosomes af-
fecting genes encoding BRCA2 or both chromosomes 
affecting FANCN genes are especially prone to de-
velop AML.
Alter et al 2007, 
Tischkowitz et al  
(2010)
AML, CML
BCR/ABL fusion protein inhibits the formation of 
nuclear FANCD2 foci
Valeri et al 2010
AML
NPM is a substrate for BRCA1-BARD1.  In AML in 
China, where pollution is high, NPM1 is frequently 
lost. NPM1 locus on chromosome 5 is part of a 
region that modifies breast cancer risk in BRCA1 
related breast cancers. 
Sato JBC 2004; Wang 
et al 2010;  Nathan-
son and Weber 2002
AML
ATM mutations increase the incidence of transloca-
tions at 11q23 involving the multi-lineage leukemia 
gene (MLL).  ATM prevents oncogenic translocations 
Bredemeyer et al 
2006; Sun et al, 2010
Myeloid leuke-
mias
Frequent loss of chromosome 17 [monosomy 17] 
containing BRCA1 and p53
Zhu et al 2008
Acute promyelo-
cytic leukemia 
(APL)
PML fusion protein with retinoic acid receptor causes 
loss of PML protein function.  PML is essential for 
proper localization of RAD51 in nuclear foci and effi-
cient homology directed repair.  PML also participates 
in localizing BRCA1.   
Boichuk 2011
Acute promyelo-
cytic leukemia 
(APL)
BRCA1 expression is reduced 3 to 14.3 fold in APL Casorelli et al 2006
Fanconi anemia 
associated can-
cers especially 
AML
 The model in Fig 3 shows how Fanconi proteins are 
required for activities of BRCA1 and BRCA2.
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to14.3 fold in MSH6, MLH1, BRCA1 and RAD51 
expression in all APL samples. 
The promyelocytic leukemia protein 
(PML) is a tumor suppressor.  At first this func-
tion seemed restricted to leukemia but was soon 
extended to solid tumors.  PML is critical for 
forming nuclear bodies with important functions 
in transcription, apoptosis, DNA repair and an-
tiviral responses.  BRCA1 colocalizes with these 
nuclear bodies which may be essential for chro-
matin remodeling [Luciani et al (2006)].  The gene 
is often involved in the translocation with the 
retinoic acid receptor alpha gene.   This results in 
loss of PML function and is associated with acute 
promyelocytic leukemia (APL).  PML expression 
is also lost in some solid tumors, the loss corre-
lating with tumor progression.  PML is critical for 
proper localization of the essential repair protein 
Rad51 in nuclear foci, and for efficient homology-
directed repair.  In cells expressing SV40 large T 
antigen, Rad51 foci depend on PML (Fig. 3).  PML 
participates in localizing, or otherwise regulating, 
additional factors with links to the pathway in Fig. 
2.  These include BLM, MRN, RPA and BRCA1 
[Boichuk et al, 2011].
In myeloid leukemias, chromosome 17 
(containing BRCA1) is frequently lost or involved 
in complex chromosomal abnormalities includ-
ing balanced translocations involving the BRCA1 
locus [Zhu et al (2008)].  Some pathogenic 
mechanisms in leukemias may be related to those 
in hereditary breast cancers.   
Mutations in pathways depending on 
BRCA1/2 genes increase risks for myeloid 
leukemia.  
Associations between BRCA1/2 mediated 
pathways and myeloid leukemia were indepen-
dently tested against mutation related risks for 
myeloid leukemia.   This association is especially 
strong for homozygous or biallelic mutations in 
BRCA2 (Fanconi protein D1).  Six children with 
biallelic BRCA2 mutations all developed leukemia at 
median age 2.2 years, with 4 of 6 developing acute 
myeloid leukemia (AML) [Wagner et al. (2004)].  
Biallelic BRCA2 mutation patients have a 79% cumu-
lative probability of leukemia (primarily AML) by age 
10 years [Alter et al. ((2007)] (Table 2).  
Homozygous or biallelic mutations in 
BRCA1 are incompatible with human life but het-
erozygous BRCA1 mutations are well known.  Car-
riers of heterozygous mutations in either BRCA1 or 
BRCA2 have increased risks for myeloid leukemia.  
Rows 3 through 16 of Table 2 summarize risks for 
myeloid leukemia from 14 studies of known/poten-
tial heterozygous BRCA1/2 mutation carriers or 
individuals eligible for mutation testing.  Most stud-
ies reported elevated risks for leukemia or other 
hematopoietic cancers.  Risks may be even greater 
because none of the heterozygote studies included 
populations that had all tested positive for mutation 
and very ill cancer patients may have been lost to 
follow up. 
Mutations in Fanconi anemia genes.  
Fanconi anemia is an inherited cancer condition 
caused by inactivation of one of 13 Fanconi anemia 
complementation groups.  In Fanconi anemia pa-
tients, summary relative risks for AML were 703.3 
[363.7–1354.5] [Friedenson (2007)].   This suggests 
that functional Fanconi proteins are essential to 
prevent generation of cancer stem cells and AML 
[Tischkowitz et al. (2004)].   Few stringent geno-
type–phenotype connections have emerged for 
Fanconi anemia.  Other genes and environmental 
factors may modify the phenotype [Neveling et al. 
(2009)].
Mutations in Fanconi genes contribute to 
a subset of sporadic AML [Lensch et al. (2003), 
Condie et al. (2002), Xie et al. (2000)].  In heterozy-
gous carriers, lymphocytes show increased sensitiv-
ity to mutagens, but are not blocked in G2 phase 
as in full Fanconi Anemia [Rischewski et al (200), 
Mohseni et al. (2009].   Heterozygous mutation in 
the Fanconi J gene prevents the encoded helicase 
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Table 2.  Risks of leukemia and oral cavity cancers as cancers following breast, ovarian or fallopian 
tube cancer in proven or potential BRCA1/2 mutation carriers
Row number, Study population and 
reference
Mutation test status
Risk measurement for leukemias [Con-
fidence interval]
1. 6 children with biallelic BRCA2 
mutations [Wagner (2004)].
Biallelic BRCA2 mutations (com-
pound heterozygotes)
All developed leukemia at median age 2.2 
years.  4 of 6 AMLs 
2. Review of 27 biallelic BRCA2 muta-
tion patients [Alter (2003)]. 
Biallelic BRCA2 mutations (com-
pound heterozygotes)
79% cumulative probability of leukemia 
(primarily AML) by age 10 years  
3.   First breast cancer age <45 in 6958 
Connecticut women.  [Harvey & Brin-
ton, 1985]
Potential mutation carriers eligible 
for mutation testing
Acute non-lymphocytic leukemia as 2nd 
cancer O/E=2.9 at 1-4 years and 6.4 at 
5-9 years 
4.   Breast cancer patients, age 35-49 from 
26,617 primary female breast cancers 
[Teppo et al, 1985]
Potential mutation carriers eligible 
for mutation testing
Subsequent leukemia (excluding CLL) RR= 
3.21 p<.01
5.   Female breast cancer surviving >= 10 
years (selects 11,273 younger patients) 
[Ewertz & Mouridsen, 1985]
Potential mutation carriers eligible 
for mutation testing
Acute non-lymphocytic leukemia as a 2nd 
cancer RR=2.3
6.   2813 women with 2 breast or ovarian 
cancers in Thames Cancer Registry. 
[Evans et al, 2001b]  
Potential BRCA1/2 mutation carri-
ers eligible for mutation testing Myeloid leukemia RR=5.04 [1.85-11.0]
7.   82,520 Women with breast cancer age 
<=45 in 13 cancer registries. [Mellemk-
jaer et al, 2006]
Potential mutation carriers eligible 
for mutation testing
Myeloid Leukemia  SIR = 3.02 (2.32–3.85) 
Leukemia SIR = 2.16 (1.78–2.59).
8.   2,084 Women with primary fallopian 
tube cancer from 13 cancer registries 
[Riska et al, 2007]
Probable BRCA1/2 mutation car-
riers.  Non-lymphoid leukemia RR=3.7 (1.0-9.4) 
9.   2nd cancer after Breast Cancer<50. 
from 32, 799 patients in Thames Can-
cer Registry. [Evans et al, 2001a]
Potential BRCA1/2 mutation carri-
ers eligible for mutation testing Myeloid leukemias RR=2.31 [1.52-3.51]
10.   2nd cancer after male breast cancer 
[Hemminki et al, 2005] 
Men at high risk for being (BRCA2) 
mutation carriers eligible for muta-
tion testing
Myeloid leukemia RR=3.98 [1.46 – 8.67] 
1-9 yrs of follow up.  RR=3.42 [1.47-6.73] for 
all periods
11.   534 First degree relatives of BRCA1  
probands with ovarian cancer [Risch 
et al, 2006]
Tested BRCA1 heterozygotes or 
potential carriers eligible for testing
Leukemias, lymphomas, etc RR=3.7 (1.5 
to 9.5) 
12.   7/98 multiple primary cancer fami
lies with a BRCA1 mutation and 
8/98 multiple primary cancer fami
lies with a BRCA2 mutation 
[Shih et al, 2000]
Known BRCA1 and BRCA2 muta-
tion carriers
20% of leukemias in the families occurred 
in BRCA1 and BRCA2 mutation carriers.  
13.   3678 women, 50 men. 1st degree 
relatives of BRCA2 mutation car-
riers or of breast or ovarian cancer 
patients [Breast cancer linkage 
consortium, 1999] 
471 BRCA2 carriers, 390 noncar-
riers, and 2186 unknown BRCA2 
carrier status 
Leukemia RR= 1.12 [0.30–4.25]
14.   11847 individuals from 699 families 
segregating a BRCA1 mutation 
[Thompson et al, 2002]
18.9% (2245) tested BRCA1 car-
riers, 9.3% (1106) tested negative, 
71.7% (8496) untested.  
Leukemia RR = 0.88 [0.37 to 2.14] p=.83 
15.   1811 male and female family mem
bers [Van Asperen et al,  2005]
50% probability BRCA2 mutation 
from 139 BRCA2 families. Leukemia RR= 1.5 [0.5 to 3.5]
16.   728 males & females (BRCA2). 
1145 males & females (BRCA1) 
[Johannson et al, 1999]
From families with an identified 
BRCA2 or BRCA1 mutation
Acute leukemia SMR=1.54 [0.04±8.59] 
(BRCA2). 1.01 [0.03±5.62] (BRCA1)
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Studies of heterozygotes or potential heterozygotes listed in Table 2
The Breast Cancer Linkage Consortium (1999).  Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst.  91: 1310-1316.
Evans H, Lewis C, Robinson D, Bell C, Moller H, Hodgson S. (2001a).  Incidence of multiple primary cancers in a cohort of women diagnosed 
with breast cancer in southeast England. Brit J Cancer 84: 435-440 
Evans H., Lewis, C., Robinson, D. et al. (2001b) Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility. 
Int J. Cancer 94: 758-9
Ewertz, M. & Mouridsen, H.  Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr. 1985; 
88:325-9
Harvey EB and Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935–1982. Natl Cancer Inst Monogr 1985; 68, 
99–109
Hemminki K, Scélo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride M, Kliewer EV, Chia KS, Pompe-Kirn 
V, Martos C, Jonasson JG, Li X, Brennan P.  (2005)  Second primary malignancies in patients with male breast cancer.  Brit. J. Cancer 92 : 
1288-92. 
Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumors in relatives of BRCA1 and BRCA2 germ-
line mutation carriers (1999). Eur J Cancer 35:1248–57
Mellemkjaer L, Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-
Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P.  (2006). Risk of second cancer among women with breast cancer. Int J 
Cancer 118(9):2285-92.
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA.  (2006) Population BRCA1 and BRCA2 
mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 98(23):1694-706.
Riska A, Pukkala E, Scélo G, Mellemkjaer L, Hemminki K, Weiderpass E, McBride ML, Pompe-Kirn V, Tracey E, Brewster DH, Kliewer EV, Tonita 
JM, Kee-Seng C, Jonasson JG, Martos C, Boffetta P, Brennan P.  (2007)  Second primary malignancies in females with primary fallopian 
tube cancer. Int J Cancer 120(9):2047-51.
Shih H, Nathanson K, Seal S, Collins N, Stratton M, Rebbeck T and Weber B. (2000).  BRCA1 and BRCA2 mutations in breast cancer families 
with multiple primary cancers. Clin Cancer Res 6, 4259-64. 
Teppo L, Pukkala E and Saxen E.  (1985)  Multiple cancer – an epidemiological exercise in Finland. J Natl Cancer Inst 75: 207–217.
Thompson D, Easton DF; Breast Cancer Linkage Consortium (2002).  Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 
94(18):1358-65 
van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Ho-
gervorst FB, van Houwelingen JC, van’t Veer LJ, Rookus MA, van Leeuwen FE; Netherlands Collaborative Group on Hereditary Breast Cancer 
(HEBON). (2005)  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 42(9):711-9.
Footnotes:  NR= Not reported.  Confidence intervals are given in brackets.  #RR=1.1 for mouth cancer.  * Head/neck and 
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from unwinding DNA [Wu et al. (2010]], suggest-
ing one mechanism.    
ATM mutations.   ATM may prevent 
oncogenic translocations by preventing exces-
sive loading of recombinational repair proteins 
onto translocation breakpoint cluster regions 
(“hotspots”) [Bredemeyer et al. (2006)].  Chro-
mosomal translocations involving the MLL (Multi 
Lineage Leukemia) gene on chromosome 11q23 
are very common in infantile and secondary leu-
kemias.  The ATM gene is near MLL and ATM de-
ficiencies increase the incidence of 11q23 trans-
locations in a fibroblast cell line and fluorescence 
in situ hybridization analysis shows split MLL gene 
signals are more numerous in cells after DNA 
damage.  
The MLL gene is one of the few genes 
with multiple translocation partners in leukemias. 
More than 70 MLL translocations have been 
reported in de novo and therapy related AML 
or ALL.  A strong non-homologous end joining 
repair signature exists at all of these chromosome 
translocation breakpoint junctions. Most other 
chromosome translocations in leukemia have no 
consistent homologous sequences at the break-
points [Zhang and Rowley, 2006].  
Most breakpoints occur within an 8.3 kb 
breakpoint region within exons 7-13 of the MLL 
gene.   MLL rearrangements at the 11q23 break-
point cluster region are strongly linked to AML, 
representing a WHO subtype found in approxi-
mately 15% of patients with AML and ALL.  
There are isolated reports of AML associ-
ated with ATM mutation, but malignancies in the 
lymphoid branches of hematopoetic cell develop-
ment are common.   Lymphoid malignancies may 
represent competing risks. 
Risks for cancers of the oral cavity 
in mutation carriers.  Acetaldehyde is strongly 
suspected in cancers of the upper aerodigestive 
tract.  Formaldehyde is linked to nasopharyngeal 
and sinonasal cancers [Baan et al. (2009), National 
Toxicology Program (2010)]. The annual incidence 
of nasal tumors in the United States is < 1 in 
100,000 people per year.  Such rare outcomes are 
difficult to study due to a lack of statistical power.  
Searches in homozygous mutation carriers however 
found that cancers of the oral cavity are the most 
frequent solid tumors in Fanconi homozygotes with 
relative risk >200 times normal [Alter et al. (2007)].  
For heterozygotes or potential heterozygotes, the 
disease may be too rare to allow a sufficient sample 
size to properly evaluate risks.  
Formaldehyde, acetaldehyde and leu-
kemias.  Formaldehyde is now a proven cause of 
human myeloid leukemia.   Myeloid leukemia devel-
ops at 2 – 5.9 ppm formaldehyde in air.   
Myeloid leukemia was a prototype in formu-
lating the cancer stem cell theory.  Search results 
in model systems show a connection between 
formaldehyde and stem cell damage.  As measured 
by increases in characteristic stem cell pathways,  
formaldehyde activates and damages stem cells 
during carcinogenesis.  [Andersen et al. (2010)].  
Other model studies show that ethanol can in-
duce oxidative DNA damage via the metabolism 
of ethanol by the ADH1B/ALDH2 pathway[Yan et 
al. (2011)].   Lipid oxidation products are increased 
in myeloid leukemia.  Some of these products 
resemble crotonaldehyde, an intermediate in acet-
aldehyde metabolism (Fig 2).  Rats fed acetaldehyde 
in their drinking water have increased incidence of 
leukemias, lymphomas and the benign breast tumors 
fibroadenomas and fibromas.  
Searches of epidemiologic studies found 
potential associations between acetaldehyde and 
myeloid leukemias.   Alcohol consumption during 
pregnancy may increase risk for childhood AML 
(Latino-Martel et al (2010).  Odds Ratios of 10.48 
[2.8- 39.1] were reported for leukemia in children 
born to women who drank during the second or 
third trimester of pregnancy [Shu et al (1996)].
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Acetaldehyde, formaldehyde and breast 
cancer risks 
Acetaldehyde forms during alcohol 
metabolism (Fig. 2a) and the system can be 
saturated.  Overwhelming natural metabolic 
systems by excess drinking or inheriting variant 
combinations of enzymes in metabolic path-
ways can raise acetaldehyde levels.  Acetalde-
hyde alone is a complete carcinogen, at least in 
rodent nasal epithelium where it causes nasal 
tumors and squamous cell carcinomas.   Many 
studies have found that acetaldehyde increases 
the frequency of sister chromatid exchanges 
and aberrations in mammalian cells.   Exposure 
of DNA to acetaldehyde results in a DNA 
interstrand cross link and other lesion respon-
sible for carcinogenic properties of crotonalde-
hyde.  Histones and naturally occurring poly-
amines facilitate the formation of these lesions 
[Brooks, Theravathu.(2005); Sako et al (2003)].
Acetaldehyde detoxification can deplete 
antioxidant defenses and generate oxygen spe-
cies that cause additional complex DNA dam-
age.   Acetaldehyde is a very good substrate for 
other enzymes present in breast cells: xanthine 
oxidoreductase (XOR) and aldehyde oxidase 
(AOX) [Shaw et al (1989), Dumitrescu and 
Shields  (2005)].   As they convert acetaldehyde 
to acetate, both these enzymes can gener-
ate reactive oxygen species i.e.  superoxide, 
hydroxy radical and hydrogen peroxide.  Both 
enzymes are present and regulated in breast 
tissues.  Decreased xanthine oxidoreductase is 
associated with worse prognosis in ovarian car-
cinoma   Breast cancers that lack cytoplasmic 
XOR have about a 2.5 greater risk of metas-
tases than those with strong XOR expression 
[Linder et al. (2005)].  The generation of free 
radicals is also associated with the reaction 
catalysed by cytochrome P-4502E1. [Jelski et 
al (2006)] Breast tissue can convert ethanol to 
acetaldehyde and free radicals [Maciel et al (2004)]. 
Model system searches found several stud-
ies report that acetaldehyde causes complex DNA 
adducts and damage that requires BRCA1/2 path-
way mediated repairs [Marietta et al 2009; Na-
kano et al (2003, 2009)].   Acetaldehyde increased 
chromosomal aberrations in Fanconi anemia cells 
much more than in normal cells [Obe et al (1979)].  
Meanwhile ethanol may suppress BRCA1 levels [Fan 
et al (2000)].   
Acetaldehyde occurs in breast milk and 
breast feeding mothers transfer it to infants.  An 
exaggerated blood acetaldehyde response that 
has been reported after ethanol administration to 
pregnant rats begins a much larger alteration during 
lactation.  At the end of pregnancy, there is a 4-fold 
increase in the acetaldehyde above nonpregnant 
values after an intragastric dose of 3 g/kg ethanol. 
During gestational days 1 to 17, the levels did not 
differ.  After delivery, the exaggerated acetalde-
hyde response to ethanol was increased, producing 
acetaldehyde concentrations 15-fold greater than in 
nonlactating controls [Gordon et al (1985)].
Over 100 published studies find that drink-
ing alcohol increases breast cancer risk.  Search 
results found epidemiologic studies consistent with 
increases in breast cancer risk in BRCA1/2 muta-
tion carriers caused by acetaldehyde.    Four studies 
in Table 3 show early onset breast cancer associated 
with alcohol genotypes that allow rapid production 
or accumulation of acetaldehyde.   One additional 
result [Moorman et al (2011)] shows that women 
who are potential or known mutation carriers get 
breast cancer sooner if they consume alcohol.  
Women with an efficient alcohol dehydro-
genase produce higher levels of acetaldehyde.  The 
relationship between ADH1C polymorphism and 
cancer only can be studied in populations with 
significant alcohol consumption [Seitz and Becker 
(2007)].  Mitochondrial damage in this popula-
tion may contribute to elevateld acetaldehydelev-
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Cannizzaro et al (2010)].  The enzyme encoded by 
ADH1C not only converts alcohol to acetaldehyde 
but may also participate in estrogen metabolism.  
In premenopausal women alcohol associates with 
higher blood estrogen levels although some stud-
ies found this only occurred in women using oral 
contraceptives.  Even small amounts of alcohol 
given to healthy women led to an increase in es-
tradiol of 27-38% when alcohol was detectable in 
the blood  [Coutelle et al (2004)]. 
In contrast to evidence linking alcohol 
and acetaldehyde to breast cancer, similar links to 
formaldehyde are almost non-existent.  Greater 
numbers of DNA-protein cross-links were found 
in the white cells of breast cancer patients than in 
matched controls [Wu et al. (2002)].  Higher activ-
ity of ALDH1 (cytosolic) aldehyde dehydrogenase 
in BRCA1 breast stem cells and hematopoietic 
cancer stem cells suggests less ability to remove 
aldehydes and greater susceptibility to mutagenic 
els.  Negative results have been reported when 
very high percentages of breast cancer patients 
(>=70%) are non-drinkers or light drinkers.
Evidence from breast cancer clusters on 
Long Island, New York also suggests that alcohol 
may increase risk in mutation carriers.  Women 
who lived in this area and developed breast can-
cer were more likely to use alcohol and to have 
risk factors associated with BRCA mutations.  
BRCA mutation related risk factors included 
Ashkenazi Jewish heritage and a family history of 
breast cancer.     
 Adding risks from BRCA1/2 pathway mu-
tations to those from rapid alcohol metabolism 
and estrogen elevation may make some women 
at especially high cancer risks from alcohol use.   
Acetaldehyde elevation in drinkers associates 
with high estrogen menstrual phases and with 
oral contraceptive use [Eriksson et al (1996), 
Reference Patients Results
Freudenheim et al 
(1999)
134 premenopausal, 181 postmenopausal  
breast cancer patients an efficient form 
of ADH vs controls with similar alcohol 
intakes
OR=3.6[1.5-8.8] premenopaus-
al breast cancer
Vachon et al (2001)
Daily drinkers who were first degree rela-
tives of breast cancer probands
RR=2.45 [1.2-5.02]
Terry et al (2006)
>1000 breast cancer patients and fast alco-
hol metabolizers sing data from the Long 
Island, NY Breast Cancer Study Project. 
Premenopausal risk 
OR=2.9[1.2-7.1]  for 1-2 drinks 
per day
Coutelle et al (2004)
ADH1C genotype in 117 moderate alco-
hol consumers with breast cancer.  The 
ADH1C*1 allele was significantly more fre-
quent in moderate alcohol consumers with 
breast cancer vs. age-matched alcoholic 
controls without cancer (62% vs. 41.9%)
Women with the ADH1C*1,1 
genotype were 1.8 times more 
at risk for breast cancer than 
those with another genotype
Moorman et al. (2011)
Females age >=20 diagnosed with breast 
cancer and tested for BRCA1/2 mutations.  
283 BRCA1 and 204 BRCA2 positive cases
BRCA1/2 mutation carriers 
got breast cancer up to nearly  
four years younger if they con-
sumed alcohol
Table 3 Epidemiologic studies of acetaldehyde/alcohol and early  onset breast cancers
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effects.  Formaldehyde in the environment has 
been positively associated with breast cancer risk 
[Coyle et al. (2005)].  
Mutation carriers have widely vary-
ing cancer risks.  Female mutation carriers have 
high risks for early onset breast /ovarian cancer as 
a group but many stiudies were found showing in-
dividual risks within this group vary greatly.  There 
is no single risk associated with BRCA1 or BRCA2 
carrier status [Begg et al. (2008)].  Defective BRCA 
genes increase risks for cancers in organs other 
than breast and ovary but individual mutation car-
riers again differ greatly [Friedenson (2005)]. These 
results implicate an increased susceptibility in or-
gans exposed to environmental carcinogens and/or 
deficits in additional genes [Friedenson (2010a)].   
There are unrelated examples of inherited 
cancer associated conditions that have increased 
susceptibility to environmental carcinogens.   
Common findings are increased sensitivity to 
cancer associated infections, to radiation, and to 
chemical carcinogens.  This shows that the phe-
nomenon of increased sensitivity to environmental 
carcinogens formaldehyde and acetaldehyde are 
probably representative of a broad general phe-
nomenon.  
Discussion
 Treatment related risk factors for 
myeloid leukemia.   The pathway connections 
in Fig. 3 suggest that any cause of myeloid leuke-
mia should be over represented because inherited 
BRCA1/2 pathway defects predispose to myeloid 
leukemias.   Adding cancers related to known 
infectious agents stresses the influence of enviro-
mental carcinogens.
However risks also include treatment 
related risks for breast cancer due to chemo-
therapy and radiation treatment.  The lack of data 
separating risk factors from treatment risks makes 
it difficult to determine how much of the excess 
risks might be associated with treatment.  This is 
especially difficult because the median age for diag-
nosis of AML is 67.  Myeloid leukemias therefore 
normally occur after early onset breast cancers.  
Early onset breast cancer patients treated with 
certain chemotherapy drugs are more likely to 
develop AML. Some of the drugs linked with 
these secondary (treatment related) leukemias 
include mechlorethamine, procarbazine, chloram-
bucil, melphalan, etoposide, teniposide and cyclo-
phosphamide. Combining these drugs with radia-
tion therapy further increases the risk. [Casorelli 
et al (2003)].  
Several publications in Table 2 addressed 
this issue directly or provide some data that does. 
Hemminki et al (Table 2) noted that there was 
no trend for increasing risk for myeloid leukemia 
with follow up time.  The first chemotherapy 
regimen for breast cancer was not published until 
1975 with large trial results appearing in 1976 
[DaVita and Chu (2008)].  Three 1985 studies in 
Table 2 include patients diagnosed with breast 
cancer before adjuvant chemotherapy became 
widely used.  In comparison to later studies, the 
three pre-chemotherapy studies in Table 2 do not 
show substantially less risk for AML than the later 
studies.  In the Harvey and Brinton study,  women 
over 55 had no excess risk for any second can-
cer while women younger than 55 still had over 
3 times the risk for myeloid leukemia.  Neither 
group was likely to receive routine chemotherapy. 
Teppo et al (Table 2) found no difference vs age 
in subsequent new primary cancers in 1953-79 in 
any age group.   Observations of approximately 
the same risk for AML before and after 1975 is 
not compatible with the fact that chemotherapy 
was given to a larger proportion of breast cancer 
patients during later periods [Table 2, Mellemk-
jaer, et al (2006) Evans et al, (2001a)]    
AML occurs with virtual certainty in 
children and infants with biallelic mutations in 
BRCA2. AML also occurs at very young ages 
in Fanconi anemia patients, before any chemo-
therapy or radiation has been given. Moreover 
defects in pathways requiring normal BRCA gene 
function are associated with other hematopoietic 
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malignancies that are not generally considered to 
be therapy related [Friedenson, 2007].
A few more recent studies in Table 2 show 
no excess risk for myeloid leukemia, consistent with 
environmental or additional genetic variation.   Al-
though some platinum cheotherapy did significantly 
raise risks for myeloid leukemias, relative risks for 
myeloid leukema these risks are only sightly higher 
than the other studies [Table 2 Riska et al (2006)].  
Radiation therapy. Therapeutic doses 
of targeted field radiation cause very little or no 
increased risk of myeloid cancers.  This is consistent 
with myeloid stem cells being more radiation resis-
tant than non-stem cells.
Despite younger ages, breast cancer patients 
with BRCAI/2 mutations present at a similar stage, 
display a normal acute reaction to radiotherapy 
and have a similar prognosis compared to sporadic 
breast cancer patients [Gaffney et al (1998)].   An 
increased risk of radiation therapy related-AML 
is largely confined to young women with stage III 
breast cancer, (spread to lymphoid tissue). These 
patients are more likely to receive radiation in 
some combination with cytotoxic chemotherapy. In 
stage 1 disease, radiation is given alone and there is 
very little excess risk for AML [Martin et al, 2009].   
Harvey and Brinton (1985) found only minor differ-
ences in AML risks for women given radiotherapy 
vs those who were not.  
Activities of detoxification pathways 
may further stratify risks.  High levels of alcohol 
consumption may be necessary for carcinogenesis 
because studies with very few heavy drinkers were 
inconsistent with these results.  Other confounding 
factors include known genetic polymorphisms that 
affect activities of alcohol metabolizing enzymes and 
behavior.  Activity of alcohol and aldehyde dehydro-
genase enzymes should further stratify risks among 
mutation carriers.   
 Excess acetaldehyde (e.g. from heavy drink-
ing) that overwhelms alcohol metabolism may 
contribute to the generation of cancer stem cells 
in mutation carriers [Friedenson (2010a)].   Acetal-
dehyde dehydrogenase has even served as a marker 
that has been used to help identify cancer stem 
cells in cancers typically associated with BRCA 
mutation - breast, pancreatic and prostate cancer.    
Results here imply that carcinogens and 
differing routes of exposure at different stem cell 
activities are major sources for tissue specificity of 
cancer.  Exposure to mutagens from alcohol me-
tabolism occurs primarily in the digestive tract and 
liver but acetaldehyde, alcohol and detoxification 
enzymes all occur in the breast.  Inherited differ-
ences in the intrinsic ability to metabolize alcohol 
or to detoxify other carcinogens contributes to de-
termining the organs where cancer occurs.  Further 
studies of relationships among genetic inheritance, 
cancer stem cells and environmental carcinogens 
are needed. 
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